Table 3.
FDA-approved antibody drug conjugates (ADCs).
| Peptide (Trade Name) | Indication | Therapeutic Target | Route | FDA Approval Year |
|---|---|---|---|---|
| Enfortumab Vedotin-Ejfv (Padcev) | Urothelial cancer (a cancer of the bladder and urinary tract). | Nectin-4 receptor | IV | 2019 |
| Polatuzumab vedotin-piiq (Polivy) | 1. DLBCL patients whose cancer has returned or has stopped responding to other treatments and who cannot have a bone-marrow transplantation. 2. Relapsed or refractory DLBCL, NOS, after undergoing at least two prior therapies interventions. |
CD79b | IV | 2019 |
| Fam-trastuzumab deruxtecan-nxki (Enhertu) | Unresectable or metastatic HER2-positive breast cancer and concomitantly has unresectable or metastatic NSCLC. | Human epidermal growth factor receptor-2 (HER2) |
IV | 2019 |
| Belantamab Mafodotin-Blmf (Blenrep) | Relapsed or refractory multiple myeloma. | B-cell maturation antigen (BCMA) | IV | 2020 |
| Tisotumab Vedotin-Tftv (TIVDAK) | Recurrent or metastatic cervical cancer with disease progression following chemotherapy. | Tissue factor TF011 | IV | 2021 |
| Loncastuximab Tesirine-Lpyl (Zynlonta) | Relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL. | CD19 | IV | 2021 |
DLBCL, diffuse large B-cell lymphoma; IV, intravenous; NOS, not otherwise specified; NSCLC, non-small-cell lung cancer.